07/22/2026 | Press release | Distributed by Public on 07/22/2026 14:36
OAKLAND - California Attorney General Rob Bonta today joined a coalition of 23 attorneys general in filing an amicus brief in support of the manufacturers of mifepristone in Louisiana v. FDA. Since the U.S. Food and Drug Administration (FDA) approved mifepristone in 2000, an estimated 7.5 million people in the United States have used the medication safely. Mifepristone, when used in combination with misoprostol, is the FDA-approved regimen used to terminate a pregnancy through 10 weeks. In today's amicus brief, the coalition urges the U.S. Court of Appeals for the Fifth Circuit to reject Louisiana's request to reinstate a medically unnecessary requirement that mifepristone be dispensed in person. Today's filing comes as the case returns to the Fifth Circuit for a merits determination after the U.S. Supreme Court allowed continued access to mifepristone in May 2026 while the litigation proceeds.
"For more than two decades, mifepristone has been proven safe and effective," said Attorney General Bonta. "Science - not politics - should guide medical decisions. California will continue to protect access to reproductive healthcare."
Medication abortion now accounts for 63% of all abortions in the formal U.S. healthcare system, with approximately one in four abortions provided via telehealth. In the amicus brief, Attorney General Bonta and the coalition argue that:
In filing today's amicus brief, Attorney General Bonta joins the attorneys general of Arizona, Colorado, Connecticut, Delaware, the District of Columbia, Hawaiʻi, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Jersey, New Mexico, New York, North Carolina, Oregon, Rhode Island, Vermont, Virginia, and Washington.